Skip to main content
  • Home
  • Library
  • Read
    • Popular
    • Charts
    • Browse
    • Categories
    • Wikis
    • Glossary
  • Request
  • Activity
  • Leaderboard
  • Help
Our Apps
  • DaoSearch
  • Narratorr
Social
  • Discord
  • Patreon
I Can Extract Side Effects
Chapter 512

Eli Lilly Goes Berserk

2,790 words 9 min read 1 view 3mo ago Source ​
Skip to the end of the chapter
Prev
Next

As a global pharmaceutical giant, Three Purities's every move attracts the attention of its competitors.

As clinical data on Oral Insulin is continuously disclosed on official websites, other insulin manufacturers are filled with trepidation and despair.

They did try Oral Insulin, but the results were dismal. They were unable to overcome the hurdle of absorption in the digestive tract and soon gave up.

Novo Nordisk once made a high-profile foray into Oral Insulin research and development, claiming to invest $3.6 billion and planning to launch the product within ten years. However, it halted the business three years later.

Because their Oral Insulin has difficulty crossing the intestinal barrier and has a particularly low bioavailability, it means that one pill requires more insulin than an injection, with most of it being wasted on the way, unnecessarily increasing production capacity pressure.

Pfizer once developed and launched the first inhaled insulin, but due to poor dosing flexibility and low acceptance, it was withdrawn from the market the following year, and the $2.7 billion investment went down the drain.

Sanofi also invested $2 billion and spent seven years developing another inhaled insulin, but due to its low peak bioactivity and the risk of affecting lung function with long-term use, the market did not accept it at all, and sales were less than $5 million a year. It had to be withdrawn from the market after two years.

Therefore, the Oral Insulin race is littered with the corpses of major pharmaceutical giants, serving as a stark warning to future generations.

As time went on, many companies stopped trying it.

Unexpectedly, Three Purities made a breakthrough and successfully developed Oral Insulin, and even successfully entered the clinical stage.

Now, insulin injections are completely hard to sell.

After reading the reports from overseas media, Wei Kang readily accepted the advice and quickly published a paper on Oral Insulin in the latest issue of the journal "Life," which immediately attracted the attention of research institutions around the world.

Since its inception, Life has always published in Chinese. Overseas scholars initially criticized this, but gradually accepted it and began to translate the papers themselves. Some scholars with a spirit of inquiry even taught themselves Chinese in order to see the original papers as soon as possible.

This time was no exception. Major overseas research institutions were well prepared, and Chinese students were in place early. As soon as they received the Chinese version of the electronic journal, they immediately began translating it and enjoyed a smooth experience.

After reading the paper, the academic community is completely convinced of the value of Oral Insulin and is just waiting for overseas clinical trials to begin.

******

Bang bang bang!

Rex closed the office door expressionlessly, then clenched his fists and slammed them heavily on the desk, venting his anger.

As the new CEO of Eli Lilly, he is experiencing the biggest crisis of his career.

The company's stock price plummeted, and its market value evaporated by hundreds of tens of billions of US dollars in just a few days.

The advent of Oral Insulin is about to severely impact the company's core Diabetes business, which accounts for 50% of its revenue.

While GLP-1 receptor agonists and other Type II Diabetes medications may not be significantly affected, the injectable insulin business will undoubtedly suffer a major setback.

Based on this calculation, the loss of insulin alone amounts to as much as $4 billion annually.

Not to mention, the company has already aroused public outrage and is being attacked by public opinion across the country, its reputation has been completely destroyed.

It's safe to say that there couldn't be a worse situation.

After smashing the desk, Rex's anger subsided considerably, and he began to calm down and think of a solution.

Suddenly, there was a knock on the door, and the female secretary hurriedly pushed the door open and entered.

"Mr. Rex, this is terrible news. We've been charged by the prosecutor."

"What?!" Rex jumped to his feet, veins throbbing on his forehead. "What on earth happened?!"

The secretary handed over a document and said urgently, "The California Attorney General has filed a lawsuit against three insulin manufacturers— Eli Lilly, Novo Nordisk, Sanofi —accusing us of using our market influence to charge Diabetes patients excessive fees."

"One of the most important reasons is that our insulin is priced much higher in the Eagle Country than overseas, which raises suspicions of price monopoly."

"This accusation has gained a lot of public support, and even the government is putting pressure on us to implement insulin price controls as soon as possible."

"Fuck!" Rex glanced at the document, his face turned pale, and he slumped down, feeling utterly powerless to do anything about it.

He never expected the situation to deteriorate so badly, becoming a situation where everyone was condemning him and adding fuel to the fire.

"Go and convene a meeting of senior executives. We'll discuss this together." After a moment's thought, Rex waved his hand, dismissing his secretary.

Since this involves litigation, we can only resolve it together with the senior management.

However, he was also prepared that if the situation became irreparable, he would have no choice but to take the blame and resign, as was the old path.

Half an hour later, all the senior executives gathered in the conference room.

Looking at the indictment, everyone wore an expression of utter disgust.

Rex tapped the table lightly and said, "I believe everyone is well aware of the current situation the company is facing. Please feel free to offer any good suggestions you may have."

The R&D director looked indignant. "These ungrateful patients deserve to die. Don't they realize that if we hadn't invested all our profits into R&D and kept launching new products, where would they get third- and fourth-generation insulin?"

The others nodded in agreement, sharing a similar sentiment.

Rex said expressionlessly, "There's no need for complaints; nobody wants to hear them. Patients only care about the price of insulin; they can't see anything else."

The sales director hesitated and said, "Currently, the most expensive insulin in the world is in the Eagle Country, which is indeed quite different from overseas. How about we lower the price a little to make a gesture and hopefully appease the patients?"

"Anyway, we raise prices every year. If we lower them a little this year, we can raise them back up in a few years. The loss won't be too great, and at least we can get through the current situation."

Some people agreed, saying, "That's right, patients are easy to fool. As long as they see that we have really lowered the price, the public opinion will naturally calm down. Then we can find an excuse to raise it back, and no one can find fault with it."

Rex retorted, somewhat speechless, "You think you can go back up the price after lowering it? Do you think things are still the same? Have you forgotten about Oral Insulin?"

"Do you know how much insulin costs in China and Europa? The price difference is tenfold!"

He bluntly stated, "Let me tell you the truth: even if Oral Insulin is launched, it will only cost this much. At roughly the same price, why would patients choose us instead of the more convenient and better-feeling Oral Insulin?"

The executives fell silent instantly.

These words were like a bucket of cold water poured over everyone's heads; although they chilled everyone to the bone, they also brought everyone back to reality.

The price of insulin in the Eagle Country is ridiculously high, almost reaching a Smallpox. Even if Three Purities's Oral Insulin is priced higher, it can't exceed that price by much.

This creates a very awkward situation: if prices aren't lowered, they will definitely be crushed by Oral Insulin and completely lose this market.

If the price is lowered, the cost advantage might allow it to create a price difference with Oral Insulin and retain a certain market share.

After all, long-term medication is a heavy burden for Diabetes patients, and some patients with poor economic conditions are certainly willing to sacrifice the experience and choose the cheaper insulin injection.

The executives looked at each other, and after a long pause, they all expressed their agreement.

"You're right. I didn't think it through. To appease the public, we have to lower the price. To compete with Oral Insulin, we still have to lower the price."

"Fortunately, in addition to insulin, we also have a blockbuster Blood-Sugar-Lowering Drug like Dulaglutide, and our revenue is growing every year, which is enough to maintain our competitiveness in the Diabetes drug market."

"That's right. GLP-1 receptor agonist drugs generate over tens of billions of US dollars in revenue annually, while insulin only generates over $3 billion. Even if we lower prices and move towards the mid-to-low-end market, it won't have a significant impact on the company's business."

"There are relatively few patients with Type I Diabetes. I suggest that the company should focus its efforts on Blood-Sugar-Lowering Drug suitable for Type II Diabetes in the future."

"Besides its Diabetes business, the company is also performing very well in the fields of immunology and neurology, with remarkable growth. There is absolutely no need for the company to fixate on insulin, which is a crooked tree, but rather to vigorously develop other disease areas."

Rex coughed lightly and said in a deep voice, "Very good, it seems we have reached a consensus to seek a glimmer of hope by lowering prices."

"So, the next question is, by how much?"

"This..." The crowd fell silent again.

Yes, they promised a price reduction, but how much will it actually be?

Rex glanced around and continued, "My suggestion is to lower the price by 70% to show our sincerity."

The sales director was the first to lose his temper and stood up to protest, "This price reduction is way too much! Those distributors will definitely skin me alive!"

Rex's expression remained unchanged as he calmly said, "My dear sales director, please allow me to remind you that even with a 70% price reduction, our insulin is still more expensive than overseas, just not as significantly so."

"Furthermore, our competitors, besides Three Purities's Oral Insulin, include Sanofi, Novo Nordisk, and even Ganli from China, especially the latter, whose injectable insulin is sold quite cheaply and has already taken away a lot of our market share in China."

"Even after the significant price reduction of insulin, there is still a profit margin, just not as exorbitant as before."

"I believe you wouldn't want to hand over this market to generic drug manufacturers."

The sales director was speechless for a moment, then sat back down dejectedly.

"Alright, it's settled then." Seeing that no one objected, Rex made the final decision immediately.

"I will issue an announcement to reduce prices by 70%, which should appease the public, deal with the lawsuits, and at the same time boost the stock price."

"Of course, such a significant price reduction will not be implemented immediately, but will be delayed until the end of the year, before Three Purities's oral liquid insulin is launched. This period should be enough to reverse all the adverse effects and consolidate the established market."

"Everyone, let's face this reality: now that Three Purities has developed Oral Insulin, we'll basically have nothing to do with insulin in the future. Let's focus our energy on Blood-Sugar-Lowering Drug."

"Or go even further and invest in pancreatic stem cell therapy to seize a new track."

Rex quickly reported the meeting results to the board of directors, and they were approved.

There was a consensus within Eli Lilly, given the soaring sales of GLP-1 receptor agonist drugs, which have become flagship drugs generating over 10 billion in revenue each year, the company should focus all its efforts on developing this area and gradually abandon the insulin product line, which has seen a significant decline in profit margins.

GLP-1 receptor agonists are a novel type of Blood-Sugar-Lowering Drug that primarily acts on pancreatic β cells. They can inhibit pancreatic β cell apoptosis, promote β cell proliferation and regeneration, thereby promoting insulin synthesis and secretion, and achieving the goal of controlling blood sugar.

This medication is primarily suitable for patients with Type II Diabetes, because they only have damaged pancreatic beta cells and insufficient insulin secretion, unlike patients with Type I Diabetes who are unable to secrete insulin.

Since 95% of Diabetes patients worldwide are type II, GLP-1 receptor agonists have a much larger market potential, which explains why Eli Lilly made this choice.

The following day, Eli Lilly officially announced this major news.

"After a series of recent events, Eli Lilly has come to realize that insulin should not be so expensive, but should be affordable for everyone who needs it."

"Starting from the fourth quarter of this year, the prices of our two best-selling insulin products will be reduced by 70%, and the launch prices of other non-branded generic insulins will also be reduced to $25 per bottle, which will be the cheapest insulin to take during meals."

"At the same time, we will also launch a new insulin, a generic version of Sanofi insulin, priced at $90, which is 80% cheaper than the original."

"Finally, we also plan to be the first pharmaceutical company to implement an insulin price cap, limiting out-of-pocket expenses for patients with commercial insurance to $35 per month. As for those without insurance, they can log on to our website, download the Eli Lilly Insulin Value Program Savings Card, and obtain Eli Lilly insulin at the same price of $35 per month."

"The significant price reduction announced today should truly help Diabetes patients in the Eagle Country and have a positive impact on society."

"Insulin price reduction should become the new standard in the Eagle Country, and we believe that other companies and stakeholders should also reach a consensus on this point."

The news was like a major earthquake, stunning the whole world.

The financial sector was the first to react; after the stock market opened, Eli Lilly's stock price immediately fluctuated and rose by 2%.

Although it hasn't rebounded back to its original price yet, it has started to rise slowly, and it is estimated that it will recover its strength soon.

At first, netizens couldn't believe it because there had been so many twists and turns recently, and they thought the hackers had returned.

It wasn't until they saw Rex's interview on the news, and his statements were exactly the same as those announced online, that everyone finally believed it.

The Eagle Country Diabetes Association immediately issued a statement praising Eli Lilly's price reduction and expressing its anticipation for price reduction announcements from other insulin manufacturers.

As for the praise from all sectors, it came like a tidal wave. Eli Lilly's reputation was completely turned around, transforming it from a greedy vampire into a price-cutting pioneer who cared about the people.

Netizens stopped criticizing Eli Lilly and instead cheered and shared the post, urging other manufacturers to follow suit.

"I was wrong. It turns out that vampires really can repent."

"Eli Lilly has actually lowered its prices! Grandma, come out and see God!"

"Thank God, I can finally afford insulin and don't have to travel thousands of miles to buy smuggled goods anymore."

"From now on, I will only buy insulin from Eli Lilly. As for other manufacturers, they can just go to hell."

"I've made up my mind. From now on, even if I have to buy generic insulin, I will only buy Eli Lilly."

Amidst the global jubilation, the only losers are the other insulin manufacturers.

Sanofi and Novo Nordisk, in particular, were furious and wanted nothing more than to tear Eli Lilly apart.

However, with public opinion so strong, they couldn't openly oppose the price reduction. They had no choice but to secretly wipe away their tears in the toilet.

Eli Lilly's preemptive strike turned the tables, allowing them to escape unscathed and put their competitors on the spot, making them the new targets of attacks from netizens across the country.

It even cunningly copied its competitors' insulin drugs and sold them at rock-bottom prices, clearly aiming to steal market share from both companies.

This wave of capitalist backstabbing deserves a thumbs up and a shout of "Well done!" from anyone who sees it!

Just as Eli Lilly was launching a massive price cut on insulin, becoming fiercely competitive...

Three Purities's Oral Insulin has also officially entered the Eagle Country and begun Phase III Clinical Trial.

End of Chapter
Prev
NovelSummaries
Next

Explore the wiki

Wei Kang
Three Purities
China
Eagle Country

Comments

No comments yet.
AboutStatsAPIChangelogStatusContactPrivacyTermsDMCA
© 2026 RandomTranslator·v3.26·RSS